1,2,3-Triazole-fused spirochromenes as potential anti-tubercular agents: synthesis and biological evaluation

被引:45
作者
Ashok, Dongamanti [1 ]
Chiranjeevi, Pamula [1 ]
Kumar, Aamate Vikas [1 ]
Sarasija, Madderla [2 ]
Krishna, Vagolu Siva [3 ]
Sriram, Dharmarajan [3 ]
Balasubramanian, Sridhar [4 ]
机构
[1] Osmania Univ, Dept Chem, Green & Med Chem Lab, Hyderabad 500007, Telangana State, India
[2] Satavahana Univ, Dept Chem, Karimnagar 505001, Telangana State, India
[3] Birla Inst Technol & Sci Pilani, Dept Pharm, Hyderabad Campus, Hyderabad 500078, Telangana State, India
[4] Indian Inst Chem Technol, CSIR, Xray Crystallog Div, Hyderabad 500007, Andhra Prades, India
关键词
MYCOBACTERIUM-TUBERCULOSIS; DERIVATIVES; INHIBITORS; BENZODIAZEPINE; METABOLITES; BINDING; DESIGN; ROOTS;
D O I
10.1039/c8ra03197e
中图分类号
O6 [化学];
学科分类号
070301 [无机化学];
摘要
A facile and convenient approach has been designed for the synthesis of novel prototypes that possess the advantage of the two pharmacophores of chromene and 1,2,3-triazole in a single molecular backbone, were evaluated against Mycobacterium tuberculosis H37Rv strain. The new analogues 1,2,3-triazole-fused spirochromenes were accomplished in four step synthetic strategy utilizing click chemistry ([3 + 2] Huisgen cycloaddition) in the ultimate step. The synthesized compounds were established based on the spectral data and X-ray crystal structure for 7a. Among the compounds tested against Mycobacterium tuberculosis H37Rv strain, some products exhibited potent antimycobacterial activity with minimum inhibitory concentration (MIC) values ranging from 1.56 to 6.25 mu g mL(-1). Compounds exhibiting good in vitro potency in the MTB MIC assay were further examined for cytotoxicity in a RAW 264.7 cells. Compounds 7a, 7d, 7i (MIC: 1.56 mu g mL(-1)) and 7k, 7m (MIC: 3.125 mu g mL(-1)) exhibited promising hits.
引用
收藏
页码:16997 / 17007
页数:11
相关论文
共 47 条
[1]
[Anonymous], [No title captured]
[2]
[Anonymous], EUR RESPIR J S36
[3]
[Anonymous], 2017, GLOB TUB REP
[4]
1,2,3-triazolo[1,5-a]quinoxalines: synthesis and binding to benzodiazepine and adenosine receptors [J].
Bertelli, L ;
Biagi, G ;
Giorgi, I ;
Manera, C ;
Livi, O ;
Scartoni, V ;
Betti, L ;
Giannaccini, G ;
Trincavelli, L ;
Barili, PL .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 1998, 33 (02) :113-122
[5]
New 1,2,3-triazolo[1,5-a]quinoxalines: synthesis and binding to benzodiazepine and adenosine receptors. II [J].
Biagi, G ;
Giorgi, I ;
Livi, O ;
Scartoni, V ;
Betti, L ;
Giannacini, G ;
Trincavelli, ML .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2002, 37 (07) :565-571
[6]
Novel 1,2,3-Triazole Derivatives for Use against Mycobacterium tuberculosis H37Rv (ATCC 27294) Strain [J].
Boechat, Nubia ;
Ferreira, Vitor F. ;
Ferreira, Sabrina B. ;
Ferreira, Maria de Lourdes G. ;
da Silva, Fernando de C. ;
Bastos, Monica M. ;
Costa, Marilia dos S. ;
Lourenco, Maria Cristina S. ;
Pinto, Angelo C. ;
Krettli, Antoniana U. ;
Aguiar, Anna Caroline ;
Teixeira, Brunno M. ;
da Silva, Nathalia V. ;
Martins, Priscila R. C. ;
Bezerra, Flavio Augusto F. M. ;
Camilo, Ane Louise S. ;
da Silva, Gerson P. ;
Costa, Carolina C. P. .
JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (17) :5988-5999
[7]
Novel heteroarotinoids as potential antagonists of Mycobacterium bovis BCG [J].
Brown, CW ;
Liu, SQ ;
Klucik, J ;
Berlin, KD ;
Brennan, PJ ;
Kaur, D ;
Benbrook, DM .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (04) :1008-1017
[8]
Bruker, 2016, APEX3, SAINT and SADABS
[9]
1,2,3,4,8,9,10,11-Octahydrobenzo[j]phenanthridine-7,12-diones as New Leads against Mycobacterium tuberculosis [J].
Cappoen, Davie ;
Claes, Pieter ;
Jacobs, Jan ;
Anthonissen, Roel ;
Mathys, Vanessa ;
Verschaeve, Luc ;
Huygen, Kris ;
De Kimpe, Norbert .
JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (07) :2895-2907
[10]
Chackalamannil S., 2008, [No title captured], Patent No. [WO 2008,042,422, 2008042422, WO2008042422]